Aby J. Mathew Sells 425 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 425 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $10,820.50. Following the transaction, the executive vice president now owns 262,198 shares in the company, valued at approximately $6,675,561.08. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BioLife Solutions Trading Down 3.6 %

Shares of BioLife Solutions stock opened at $25.83 on Friday. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The stock’s 50-day simple moving average is $26.66 and its 200 day simple moving average is $25.49. The stock has a market capitalization of $1.21 billion, a P/E ratio of -24.37 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the business posted ($0.21) EPS. As a group, research analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several recent analyst reports. Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. TD Cowen raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. KeyCorp raised their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Finally, Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its holdings in BioLife Solutions by 31.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock valued at $1,313,000 after buying an additional 12,421 shares in the last quarter. Principal Financial Group Inc. grew its holdings in BioLife Solutions by 4.7% during the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after buying an additional 8,580 shares in the last quarter. Summit Global Investments purchased a new position in BioLife Solutions during the 3rd quarter valued at about $228,000. Curi RMB Capital LLC grew its holdings in BioLife Solutions by 0.5% during the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after buying an additional 2,283 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in BioLife Solutions during the 3rd quarter valued at about $57,000. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.